Login to Your Account

GSK Spinout Autifony Brings in $16.4M for Hearing Loss

By Nuala Moran

Tuesday, August 23, 2011
LONDON – The latest spinout to emerge from GlaxoSmithKline (GSK) plc's restructuring has raised £10 million (US$16.4 million) from venture capital (VC) investors to fund the development of drug treatments for hearing loss and tinnitus.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription